Management of Venous Thromboembolism in Patients with Hereditary Antithrombin Deficiency and Pregnancy: Case Report and Review of the Literature

Table 3

Thrombosis medical profile and antepartum prophylactic use of AT concentrate in pregnant patients with hereditary antithrombin deficiency.

Study	Study design	Number of cases	Prophylactic condition and numbers of cases		Dosage of AT used	Concurrent anticoagulation	AT concentrate initiation/duration	Goal of AT levels	Outcome
			Primary	Secondary
Ilonczai et al.; 2015	Retrospective	4	2	2	1000–2500; 2tw-3tw	LMWH	Primary, gw 11–28; gw 20–36; Secondary, gw 6–13; gw 25–29	80–120%	Miscarriage gw 28; Healthy M and N; Miscarriage gw 3; Healthy M and N
Rogenhofer et al. (2014)	Retrospective	4	1	3	1000 2tw- 2500 IU 3tw	LMWH	Primary, 3 days as initiation of LMWH at early pregnancy to delivery; Secondary, gw 6, 7, 34 to delivery	N/A	Healthy M and N
Pascual et al.; (2014)	Case report	1	—	1	3000 IU; 3tw	LMWH, UFH then warfarin at 14 wk	gw 4–15 and 11 days peripartum	>50%	Healthy M and N
Yamada et al.; (2001)	Case report	1	—	1	3000–6000 IU; weekly	N/A	gw 5–38	80–90%	Healthy M and N

AT: antithrombin, gw: gestational week, IU: international units, LMWH: low molecular weight heparin, M: mother, N/A: not available or not specified, N: newborn, UFH: unfractionated heparin, gw: gestational week, IU: international units, IVC: inferior vena cava, UFH: unfractionated heparin, 2tw: two times per week, and 3tw: three times per week.